lobbying_activities: 3490152

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3490152	8f3a5f6e-7854-4522-968c-2e8a571aefd1	Q4	DLA PIPER LLP (US)	76855	BIOTECHNOLOGY INNOVATION ORGANIZATION	2025	fourth_quarter	PHA	340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2026-01-16T15:13:09-05:00